[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Controversies in Neurology
December 1998

Interferons Should Be Used to Treat Most Patients With MS

Author Affiliations

From the Department of Neurology, G.V. (Sonny) Montgomery, Veterans Affairs Medical Center, and the Department of Neurology, University of Mississippi Medical School, Jackson, (Dr Herndon); and the Departments of Neurology, Buffalo General Hospital and the State University of New York, Buffalo (Dr Jacobs).



Arch Neurol. 1998;55(12):1581-1583. doi:10.1001/archneur.55.12.1581

TWO IFNs have recently been approved in the United States and Europe for treatment of MS. Whether to use these drugs, which drugs to use, and how to use them remains controversial. Interferon β-1b (Betaseron, Berlex, Richmond, Calif) and IFN-β-1a (Avonex, Biogen, Cambridge, Mass) were approved based on independent trials using different methods and end points, but both support the effectiveness of IFNs as a class of drugs in the treatment of MS. The IFN-β-1b trial1 was designed to show the effect of IFN-β-1b on acute attacks in patients with MS, and the IFN-β-1a trial2 was designed to show the effect of IFN-β-1a on the physical disabilities of those patients. The course of MS extends through decades, leading to significant disability with progressive decline at varying rates. Clinical trials run for 2 to 3 years. Trial end points are indicators of the long-term benefits of the drug under review. The ultimate extent and duration of the benefit of the treatment may not be known for years, but delaying irreversible change, ie, disability, is of great importance to patients with MS.

First Page Preview View Large
First page PDF preview
First page PDF preview